Get your MillionsMissing twibbon

Download the #MillionsMissing twibbon.

twibbon-example

Add the #MillionsMissing filter to your photo on Facebook and Twitter!  All it takes is the click of a button. The page also provides:

  • easy-to-use tweets and Facebook posts announcing your support for the #MillionsMissing protest
  • a place to create an email about the protest, with a form-letter and a place where you can add a personalized message
  • a widget for your site in easy to copy-and-paste htmla forum to discuss the campaign with others

Please share widely!  Help get the word out about the #MillionsMissing protest.

Posted in News | Tagged , | Comments Off on Get your MillionsMissing twibbon

CBT in CFS: a narrative review on efficacy and informed consent

Review abstract:

Cognitive behavioural therapy is increasingly promoted as a treatment for chronic fatigue syndrome. There is limited research on informed consent using cognitive behavioural therapy in chronic fatigue syndrome. We undertook a narrative review to explore efficacy and to identify the salient information that should be disclosed to patients.

We found a complex theoretical model underlying the rationale for psychotherapy in chronic fatigue syndrome. Cognitive behavioural therapy may bring about changes in self-reported fatigue for some patients in the short term, however there is a lack of evidence for long-term benefit or for improving physical function and cognitive behavioural therapy may cause distress if inappropriately prescribed.

Therapist effects and placebo effects are important outcome factors.

Cognitive behavioural therapy in the treatment of chronic fatigue syndrome: a narrative review on efficacy and informed consent, by Keith J Geraghty, Charlotte Blease in Journal of Health Psychology, 15 September 2016

Posted in News | Tagged , , , , , , , | Comments Off on CBT in CFS: a narrative review on efficacy and informed consent

ME/CFS history, diagnostic criteria & prevalence – new e-book

E-book by Mary Gloria C. Njoku, 1 Sep 2016: Myalgic, Encephalomyelitis/Chronic Fatigue Syndrome:  History, Diagnostic Criteria and Prevalence
ISBN: 978-1-4689-7326-6         Foreword by Prof Leonard Jason

Overview:

This work is a comprehensive review of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) studies that were conducted with both community-based and hospital-based samples. A review of the prevalence of fatiguing illnesses in varied countries of the world shows evidence that the rates of fatigue and its syndromes vary across settings and countries, and that the methodology used impacts findings.

Studies have also shown the presence of a severe and disabling form of fatigue that affects the ability of individuals to engage in normal occupational, educational, social and personal daily activities.

The history, definition and research findings in ME/CFS are presented to promote an understanding of the work that has been accomplished in this research area in varied continents of the world. It is hoped that some of the issues addressed in this work will help people to better understand ME/CFS and fatiguing illnesses reported in varied countries.

Perhaps, the understanding that ME/CFS is a global condition might encourage both scientists and practitioners to work towards streamlining the definition and diagnostic criteria to strengthen work in this area and ultimately improve the treatment of persons with ME/CFS.

Posted in News | Tagged , , , , , | Comments Off on ME/CFS history, diagnostic criteria & prevalence – new e-book

Choosing wisely Wales: patients in Wales urged to take more control

BBC news article, by Owain Clarke, 16 September 2016: Choosing Wisely aims for doctor-patient ‘culture shift’

Patients in Wales are being urged to take more control of decisions about the care and treatments they receive, as part of a new medical movement.

Choosing Wisely Wales aims for a more equal doctor-patient relationship.

It comes amid worries up to 20% of treatments at best do no good but at worst could harm patients – something a top doctor has called “clearly unacceptable”.

But there are fears the move might be interpreted as an effort to cut costs.

Those behind the movement, which already operates in 18 countries, want clinicians to have “open and honest conversations” about treatments, and say patients should be less passive, have more input and explore all alternatives.

Dr Paul Myres, programme leader and chairman of the Academy of Medical Royal Colleges in Wales, said:

“Amazingly, I think in Wales in particular there’s still the idea that ‘doctor knows best’ and, interestingly, some clinicians who come to work here say patients are that little more passive, not so assertive.

“We’re encouraging them to be a bit more questioning in discussions with their clinicians.”

It has been argued that if patients have “greater ownership” of the care they receive, they are more likely to follow a course of treatment, reject treatments that have little benefit, and may be less likely to return to the doctor. The approach, it has been argued, could also lead to significantly better results for patients.

Central to the idea are four questions a patient needs to ask:

_91182928_choosewiselyDr Myres admitted “there was likely to be reluctance on both sides” and said the approach could be interpreted as an attempt to save money.

“It’s not about cost-cutting, it’s about reducing waste,” he said.

“If something is wasted on a patient, then a person who really needs that treatment could face a delay.”

It is also hoped the approach could help reduce the number of “unnecessary tests and treatments”, which could result in shorter waiting times for patients with a genuine need.

This could include patients demanding antibiotics for colds and sore throats or those expecting scans for basic back pain.

But it could also involve serious diseases such as cancer, where patients might feel under pressure to accept invasive treatment which could leave them with a worse quality of life.

WHAT DO PATIENTS THINK?

John Skipper, a retired serviceman, was formerly on the board of Community Health Councils in Wales. In 2011, aged 60, he was diagnosed with prostate cancer, which he described as “a wake up call”.

“I needed to know more about my condition, I needed to know what might be the best outcome for me and be part of a team looking after me and not be on the outside looking in,” he said.

“With cancer there are many interventions possible and some carry more risks than others. Removing the prostate gland can have some real side effects.

“I was talking with my consultant and with other professionals about what other options were available to me.

“They found that useful and for me it took away a lot of the stress and I felt empowered and part of the team looking after me.”

He said the Choosing Wisely concept meant patients were part of their own care.

“It enables the doctor to do what they’re trained to do. You’re guiding them to an option that they can perform, but at least you can say ‘this is what I would prefer’,” he said.

“We often have that discussion about our car when we take it in for a service, so why can’t we have that discussion about our body?

“I think this whole culture has to be win-win for the NHS. It’s not a bottomless pit of money but it has capability and it’s about optimising the capability you have and dealing with realism.”

Physiotherapist Graeme Paul-Taylor said giving every patient with back pain a MRI scan was not the answer

WHAT DOES THE MEDICAL PROFESSION THINK?

Graeme Paul-Taylor, a physiotherapist and lecturer at Cardiff University, has a lot of experience working with patients with lower back pain.

He said there was a growing belief that sending people for a MRI scan was the “gold standard” to provide all the answers.

“What’s important is to exercise and to get moving and for a lot of people that gets them the results they need,” he said.

“But over the last couple of decades, with the real quality and sensitive scanning and imaging that can be done, people are starting to believe that the structural changes that are seen on a MRI scan are the cause of the pain.

“We know if you were to scan people with no symptoms of back pain you’re still likely to see those changes.”_91211282_choosewisely3

Dr Ffion Williams, from Prestatyn, Denbighshire, said the initiative was all about sharing information with patients.

“It’s allowing people to make their own decisions so we’re a conduit for information. It’s not the old system that we’re the doctor and ‘you do what we tell you’,” she said.

“Sometimes it’s going to be a decision from a patient that I’m not going to agree with but it’s also allowing the patient to make the decision but knowing they’ve had the right information to make it.”

Dr Myres, a former Wrexham GP, concedes consultation times may need to be lengthened.

“Really good conversations need more time up front – even though research suggests actually it can be done in 10 minutes,” he said.

“But the payback is if a patient fully understands and is involved in the decisions, they are more likely to comply and less likely to come back.”

Choosing Wisely Wales is the first campaign of its type to be launched in the UK and is being led by the Academy of Medical Royal Colleges Wales, in partnership with Public Health Wales and Community Health Councils.

Posted in News | Tagged , , , , , , , | Comments Off on Choosing wisely Wales: patients in Wales urged to take more control

Viruses and CFS: statement by Prof Robert Naviaux

Open Medicine Foundation blog post, 9 Sep 2016: Viruses and CFS: Statements by Ron Davis and Bob Naviaux

RobertKNaviaux

Dr Bob Naviaux:

Question – Many ME/CFS experts have improved the symptoms in some patients by treating with antivirals and Ampligen (polyIC double stranded RNA). I think this proves that ongoing viral infections are causing our symptoms. It is not merely “tired patients” who are stuck in a lowered metabolic state because of a past trigger (which now is gone).

First of all, it is important that people actually read our paper first before drawing conclusions from news reports and blogs and criticizing something that we never said. I have seen a number of generalizations starting to appear in blogs and reports by journalists in even good newspapers and magazines that are starting to drift too
far afield from the actual science in our paper.

We devoted a section of the paper to this and related questions about infections. The section title was: “A Homogeneous Metabolic Response to Heterogeneous Triggers”.

It concluded with the sentence:

“Despite the heterogeneity of triggers, the cellular response to these environmental stressors in patients who developed CFS was homogeneous and statistically robust.”

As background for this conclusion, I recommend reading our paper on this topic entitled, “Metabolic features of the cell danger response” (PMID 23981537).

Second, many people do not understand that the first response our body mounts against a viral, bacterial, or any kind of infection is metabolic. Yes, our chemistry is our first line of defense. Our chemistry reflects our instantaneous state of health. Innate immunity is coordinated by mitochondria and is an essential first step in developing adaptive immunity to any infectious agent. Without innate immunity there can be no antibodies and no NK cell activation, no mast cell activation, and no T cell mediated immunity.

In addition, all antivirals have metabolic effects that have nothing to do with inhibiting viral DNA or RNA synthesis directly. Many antiviral drugs inhibit the key metabolic enzyme SAdenosylhomocysteine Hydrolase (SAHH).

Inhibition of SAHH causes an increase in intracellular SAH levels. SAH is a potent inhibitor of DNA, RNA, protein, and small molecule methylation. This affects both viral and host cell epigenetics, gene expression, mRNA translation, and protein stability.

The inhibition of methylation reactions in the cell also affects neurotransmitter (dopamine, norepinephrine, and serotonin) and phosphatidylcholine membrane lipid
synthesis, folate and B12 metabolism, and many other reactions. So by giving antivirals, doctors are not just inhibiting viruses, they are also inhibiting many host cell metabolic functions.

Sometimes the inhibition of host cell functions can attenuate ME/CFS symptoms for a time, but in other cases, using potent antiviral drugs inhibits mitochondrial and methylation reactions and can delay a full recovery from ME/CFS.

Ampligen is a form of double stranded RNA called poly(IC), for poly inosinic:cytosinic acid. We have studied the action of polyIC extensively and have published this in our studies of autism and virology. It acts by binding to an innate immune receptor called TLR3, creating a simulated viral infection.

If you expose a pregnant animal to a single dose of polyIC at the beginning of the second trimester, she develops a 24-hour flu-like illness then completely recovers. However, her pups have social and cognitive abnormalities similar to autism for life. If you look at their brains, you find that they have activated microglia and brain inflammation for life.

In adults, Ampligen also binds the TLR3 receptor, and activates an incomplete antiviral response characterized by a non-MyD88 dependent activation of interferon and
other cytokines. Long-term use of polyIC carries a risk for toxicity because of chronic innate immune stimulation. In certain clinical situations like cancer or Ebola virus infection, the toxicity is actually part of the therapeutic effect.

Chronic interferon release causes flu-like symptoms, and the inhibition of mitochondrial protein translation. This can lead to secondary mitochondrial dysfunction. As I noted in an earlier Q&A response, sometimes the inhibition of mitochondrial function can make some
people with ME/CFS feel better temporarily because some symptoms can come from unbalanced overactivity of some of the hundreds of functions mitochondria perform. However, in the long term, any pharmacologic inhibition of mitochondrial function will delay a full recovery.

Third, latent and reactivated viral and bacterial infections can occur, but in the case of ME/CFS that has lasted for more than 6 months, this may be the exception rather than the rule.

Some doctors and scientists have not done a good job at educating patients and other scientists about the difference between serological evidence of infection in the form of antibodies like IgM and IgG, and physical evidence of viral replication like PCR amplification of viral RNA or DNA, or bacterial DNA.

We have learned in our autism studies with Dr. Judy Van de Water that supertiters of antibodies do not mean new or reactivated viral replication. Supertiters of IgG antibodies mean that the balancing T-cell and NK cell mediated immune activity is decreased.

This is a functional kind of immune deficiency that causes an unbalanced increase in antibodies. This is like the famous figure-and-ground illusion that shows the silhouette of two faces that also create the form of a vase.

Both things happen. But which is cause and which is effect? Increased IgG antibodies to CMV, EBV, HHV6, Coxsackie, etc. are not good evidence of a reactivated viral infection. This can be proven in most cases by trying to measure viral DNA or RNA by PCR in the blood or swollen lymph nodes. In most cases, supertiters of IgG are PCRnegative. There
are exceptions to this generalization.

Chronic PCR surveillance studies in healthy humans are showing that little waves of viral replication happen periodically throughout our lives. We have been, and are regularly infected by hundreds of viruses over a lifetime.

Sometimes this is obvious and causes a symptom like blisters or an ulcer around the mouth. However, most of the time these waves of viral replication are silent and produce no symptoms at all because they are handled in the background by the innate and cell-mediated immune system.

Even the deadly poliovirus infected 150 to 1800 people, producing only mild or unnoticed infections, for every one person who developed paralytic disease.

In most of the cases of ME/CFS that I have seen where IgG antibody titers have been measured before, during, and after antiviral therapy, the antibody titers remain high after treatment, even though the patient may report symptomatic improvement.

I believe the symptomatic improvement after antiviral treatment may have more to do with the metabolic effects of antivirals in ME/CFS than their action on viral replication. The good news is that this hypothesis can be studied scientifically and put to the test easily using the tools of PCR and metabolomics.

Good science needs to remain open, ask the questions without bias, design good experiments, take careful measurements, then have the courage to follow the data wherever they may lead.

Posted in News | Tagged , , , , , | Comments Off on Viruses and CFS: statement by Prof Robert Naviaux

Viruses and CFS: statement by Prof Ron Davis

Open Medicine Foundation blog post, 9 Sep 2016: Viruses and CFS: Statements by Ron Davis and Bob Naviaux

Prof Ron Davis:

dr-ronald-davis-stanford

There is a great deal of evidence that a variety of viruses can initiate ME/CFS, but it is less clear that a virus is involved in sustaining the disease. However, some patients may have a continuous problem with viruses, especially those viruses we always carry like EBV and HHV6.

These viruses are usually kept in check by the immune system. Any suppression of the immune system can cause reactivation of these viruses (e.g., shingles). It is possible (we have new supporting data on this) that the immune system is somewhat impaired in ME/CFS, which will make it difficult to keep these viruses suppressed. If we can find the cause of this disease and cure it, this virus problem should go away.

Also, there is a common misunderstanding about viral infection among some patients and even some doctors. Most viral assays used by doctors test for the presence of antibodies to viruses, not the viruses themselves. The presence of antibodies shows that the person had a viral infection in the past, but does not constitute evidence that it is still present.

A direct assay for a virus is needed in order to find out if any virus is present. The current state-of-the-art assay is a PCR test for DNA or RNA from a virus. (Serology tests are tests for antibodies, not viruses.)

We are conducting these direct PCR assays in the Severely Ill Patient Study, as well as extensive DNA sequencing for any as-yet-undiscovered viruses. We need to keep an open mind and have all ideas on the table and follow the data.

Our goal is to find an accurate biomarker, find the cause, find a treatment for the cause, find a cure and then prevent the disease.

 

Posted in News | Tagged , , | Comments Off on Viruses and CFS: statement by Prof Ron Davis

MPs call for medical cannabis to be made legal

BBC news article, by Michelle Roberts, 13 September 2016: MPs call for medical cannabis to be made legal

Taking cannabis for medical reasons should be made legal, says a cross-party group of UK politicians.

canabis

The All Party Parliamentary Group on Drug Policy Reform says there is clear evidence cannabis could have a therapeutic role for some conditions, including chronic pain and anxiety.

It says tens of thousands of people in the UK already break the law to use the drug for symptom relief.

But the Home Office says there are no plans to legalise the “harmful drug.”

‘I know cannabis is illegal, but it is medicinal’

Plant cannabis contains more than 60 chemicals.

The All Party Parliamentary Group wants the Home Office to reclassify herbal cannabis under existing drug laws, from schedule one to schedule four.

This would put it in the same category as steroids and sedatives and mean doctors could prescribe cannabis to patients, and chemists could dispense it.

Patients might even be allowed to grow limited amounts of cannabis for their own consumption.

People with multiple sclerosis can legally take a cannabis-based medicine.

This licensed medicine, called Sativex, is a mouth spray and contains two chemical extracts (THC and CBD) derived from the cannabis plant.

Under current laws in England and Wales, cannabis is not recognised as having any therapeutic value and anyone using the drug, even for medical reasons, could be charged for possession.

Meet the man curing sick kids with cannabis

The NHS warns that cannabis use carries a number of risks, such as impairing the ability to drive, as well as causing harm to lungs if smoked and harm to mental health, fertility or unborn babies.

The All Party Parliamentary Group on Drug Policy Reform took evidence from 623 patients, representatives of the medical professions and people with knowledge of how medical cannabis was regulated across the world.

Medicinal cannabis use        (Source: APPG/UPA survey)

  • 37   average age of patient
  • 67%  try conventional medicines first
  • 37% don’t tell their doctor
  • 72% buy street cannabis
  • 20% grow their own

Risks and benefits
Co-chair Baroness Molly Meacher said: “Cannabis works as a medicine for a number of medical conditions.

“The evidence has been strong enough to persuade a growing number of countries and US states to legalise access to medical cannabis.

“Against this background, the UK scheduling of cannabis as a substance that has no medical value is irrational.”

The group commissioned a report by an expert in rehabilitation medicine, Prof Mike Barnes, which found good evidence that medical cannabis helps alleviate the symptoms of:

  • chronic pain (including neuropathic pain)
  • spasticity (often associated with Multiple Sclerosis)
  • nausea and vomiting, particularly in the context of chemotherapy
  • anxiety

And there was moderate evidence that it could help with:

  • sleep disorders
  • poor appetite
  • fibromyalgia
  • post-traumatic stress disorder
  • Parkinson’s symptoms

But there was limited or no evidence that cannabis helps:

  • dementia mood problems
  • epilepsy
  • bladder function
  • glaucoma
  • Tourette’s syndrome
  • Huntington’s disease
  • headache
  • depression
  • obsessive compulsive disorder
  • gut disorders
  • curb cancer growth

It found short-term side-effects of cannabis were generally mild and well tolerated, but that there was a link with schizophrenia in some long-term users.

“There is probably a link in those who start using cannabis at an early age and also if the individual has a genetic predisposition to psychosis. There should be caution with regard to prescription of cannabis for such individuals,” says the report.

Also, there is a small dependency rate with cannabis at about 9%, “which needs to be taken seriously but compares to around 32% for tobacco use and 15% for alcohol use”.

The evidence for cognitive impairment in long-term users is not clear but “it is wise to be cautious in prescribing cannabis to younger people, given the possible susceptibility of the developing brain”, says the report.

Smoking cannabis in a joint rolled with tobacco can make asthma worse and probably increases the risk of lung cancer.

Prof Barnes said:

“We analysed over 20,000 scientific and medical reports.

“The results are clear. Cannabis has a medical benefit for a wide range of conditions.

“I believe that with greater research, it has the potential to help with an even greater number of conditions.

“But this research is being stifled by the government’s current classification of cannabis as having no medical benefit.”

Cannabis is currently classified as a Class B drug, with possession carrying a maximum sentence of five years in jail or an unlimited fine.

Those supplying or producing cannabis face tougher penalties, with a maximum of 14 years in jail.

The drug comes in many different forms – hash is cannabis resin, while marijuana is the dried leaves and flowers of the plant.

A Home Office spokesman said:

“There is a substantial body of scientific and medical evidence to show that cannabis is a harmful drug which can damage people’s mental and physical health.

“It is important that medicines are thoroughly trialled to ensure they meet rigorous standards before being placed on the market.

“There is a clear regime in place, administered by the Medicines and Healthcare Products Regulatory Agency, to enable medicines, including those containing controlled drugs, to be developed.”

About 24 US states, Canada, Israel and at least 11 European countries already allow access to cannabis for medical use.

Posted in News | Tagged , , , | Comments Off on MPs call for medical cannabis to be made legal

A better way to measure ME/CFS experience is needed

Research abstract:

PURPOSE:

Debilitating fatigue is a core symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); however, the utility of patient-reported symptom outcome measures of fatigue for ME/CFS patients is problematic due to ceiling effects and issues with reliability and validity. We sought to evaluate the performance of three patient-reported symptom measures in a sample of ME/CFS patients and matched controls.

METHODS:

Two hundred and forty ME/CFS patients and 88 age, sex, race, and zip code matched controls participated in the study. Participants completed the Multidimensional Fatigue Inventory-20, DePaul Symptom Questionnaire, and RAND SF-36.

RESULTS:

The general and physical fatigue subscales on Multidimensional Fatigue Inventory-20, as well as the role of physical health on the RAND SF-36, demonstrated questionable or unacceptable internal consistency and problematic ceiling effects. The DePaul Symptom Questionnaire demonstrated excellent internal reliability, and less than 5 % of participants were at the ceiling on each subscale. The post-exertional malaise subscale on the DePaul Symptom Questionnaire demonstrated excellent clinical utility as it was able to differentiate between ME/CFS patients and controls (OR 1.23, p < .001) and predicted ceiling effects on other patient-reported outcome subscales. A score of 20 on the post-exertional malaise subscale of the DePaul Symptom Questionnaire optimally differentiated between patients and controls.

CONCLUSIONS:

Significant ceiling effects and concerns with reliability and validity were observed among Multidimensional Fatigue Inventory-20 and RAND SF-36 subscales for ME/CFS patients. The DePaul Symptom Questionnaire addresses a number of concerns typically identified when using patient-reported outcome measures with ME/CFS patients; however, an improved multidimensional patient-reported outcome tool for measuring ME/CFS-related symptoms is warranted.

The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome by KW Murdock, XS Wang, Q Shi, CS Cleeland, CP Fagundes, SD Vernon in Qual Life Res. 2016 Sep 6.

Posted in News | Tagged , , , , , , | Comments Off on A better way to measure ME/CFS experience is needed

CFS is not merely dysbiosis

Psychiatry advisor article, by Theodore Henderson, MD, PhD, 2 September 2016: Chronic Fatigue Syndrome is Not Merely Dysbiosis

Dr. Henderson suggests treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with antivirals rather than with antidepressants.

Theodore HendersonMyalgic Encephalomyelitis/Chronic Fatigue Syndrome likely has a viral etiology and the strongest candidate is Epstein-Barr virus (EBV), also known as Herpes 4.

The New York Times1 on July 7, 2016 featured an article about Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) published on June 23, 2016. The Times heralds that this article “proves” that ME/CFS is not a psychological illness as it has long been scornfully conceptualized by doctors and the medical world. This is a good thing, I suppose…because it once again emphasizes that ME/CFS is a biological condition and once again emphasizes that infectious agents cause ME/CFS.

Unfortunately, it takes the medical care of ME/CFS in the wrong direction. The cited article by Giloteaux and colleagues, Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome,2 seems to ignore the extensive research demonstrating a viral etiology for ME/CFS.

The relatively small study examined the stool of 48 patients with ME/CFS for types and diversity of bacteria from the gut. Their findings – reduced diversity, increased numbers of certain species of bacteria that tend to be “pro-inflammatory,” and decreased numbers of bacterial species that are thought to be “anti-inflammatory,” along with multiple inflammatory markers. These findings hardly constitute an etiological explanation. Although the authors are careful to state that gut microbiome disruption may have a role in ME/CFS, the implication is clear – we need to fix that microbiome!

Their article leads off with descriptions of clinical improvement with probiotic therapy or rectal infusions of bacteria-laden fecal transplants. Similarly, they conclude that their findings “highlight the association of specific bacterial taxa with ME/CFS…” There is not one reference to the extensive research literature on the viral etiology of ME/CFS, or to the Institute of Medicine’s definitive review of ME/CFS, which included a conclusion that ME/CFS is likely caused by a virus.3

Perhaps I am being dogmatic, but let me explain why this is a disservice to patients. I have been treating patients with ME/CFS for years. I have heard many stories of the way medical professionals have treated them: 1) Dismissal and scorn – “I feel tired too sometimes, dear,” “Well, you would feel so much better if you just exercised;” 2) Quackery – neurofeedback, rife machines, years upon years of “anti-inflammatory” therapy; 3) Ignoring – complaints of fatigue, mental fog, joint pain go unaddressed for years; and, 4) Psychiatric labeling – diagnosing depression,.

In contrast, hundreds of patients in my care have seen improvement in 1-5 months on antiviral therapy. The Institute of Medicine committee reviewed all of the literature and spent months in deliberation before publishing their conclusions.3 High on their list of findings about ME/CFS is that it likely has a viral etiology and the strongest candidate is Epstein-Barr virus (EBV), also known as Herpes 4.

Anything that takes the public eye or the medical community’s effort away from treating ME/CFS as a viral illness is a disservice. Whether you look at the hundreds upon hundreds of patients treated by the late Dr. A. Martin Lerner4 or the hundreds of my patients who have resumed normal lives after anti-viral treatment5,6, it is hard to not feel the bile rise. Perhaps seeing it from a patient’s perspective would be helpful.

Cathy had been fatigued for years. She had to stop work as a physical therapist and barely managed to care for her children. She napped 2-3 hours every day. She could not find the energy to play with her children. And often, she was overwhelmed with anxiety. Notably, her daughter also was unusually tired for an 8 year old. Cathy came to me for help with her “depression.” She had been treated for years with antidepressants because her prior psychiatrist has said she was depressed; however, after years on antidepressants, she felt no different.

Curiously, when I interviewed her, she denied feelings of low mood, guilt, suicidal ideation, or other hallmarks of depression. She said she was tired all the time. She did not do the things she liked to do simply because she was too tired. It was not anhedonia – it was fatigue. I ran viral labs and they were extremely high. So I started her on valacyclovir, an antiviral that targets all the Herpes family virus, including EBV and Human Herpes 6 virus.

Within two months, she had more energy and was no longer napping daily. By three months, she no longer felt anxious. She was active, enthusiastic, and decided to go back to work part-time. By five months, we weaned her off her antidepressants and she was essentially symptom-free. And by the way, her bowels were fine too.

Not to paint too rosy of a picture, her daughter was not so fortunate. Her situation was different. She was always tired, often irritable, consumed at times by “stabbing thoughts” (thoughts of stabbing herself with a knife although she had no desire to die), and often anxious. We treated her with antidepressants to no avail. Alas, she also did not respond to 5 months of antiviral therapy either.

At this point, I ran labs to look for Lymes disease and Lyme-related infections. Bingo!! She had very high antibody titers for Babesia and for borrelia burgdorferi. In the hands of an expert on Lyme’s disease, she is making progress; however, her improvement is hampered by abnormalities in her immune system. Only now, with the addition of intravenous immunoglobulins (IV Ig), is she showing marked improvement in her anxiety, mood, “stabbing thoughts,” and fatigue. Unfortunately, IV Ig is very expensive and the insurance company, Blue Cross/Blue Shield, refuses to pay for it.

The family has created a GoFundMe page to try to raise the necessary money for the IV Ig (roughly $75,000 for the full course of treatment).

This little girl’s case illustrates an important point. Fatigue is a vague symptom. And, like pain, it is quite subjective. So the causes of fatigue extend far beyond one virus or one bacterium. Indeed, the causes can include thyroid abnormalities, electrolyte imbalances, cancer, blood dyscrasias, vitamin deficiencies, and infections (to name just a few).

Among these infections, we need to include viruses (particularly the Herpes viruses5), retroviruses, Lymes disease and Lyme-related infections. And we need to be open to multiple etiologies for ME/CFS. In other words, when the immune system is compromised by one infectious agent, it can become vulnerable to other infectious agents. My concern is the claims of this study by Giloteaux and colleagues, and the way those claims are exaggerated by the press, will inappropriately focus attention on gut flora in ME/CFS, leaving other causes of fatigue (as illustrated in these two cases) languishing.

Moreover, the Giloteaux article puts undue causal value on the gut bacteria for the symptoms of ME/CFS. What they label as a precipitant may, in fact, be a consequence. Let me explain… Some studies have shown Human Herpes 6 and Epstein-Barr virus can impair the function of the human immune system. If one or both of these viruses indeed cause ME/CFS, and they invade the entire body, including the gut, then they could also disrupt the immune function of the gut. So, conceivably, the viral infection created a favorable environment for the pro-inflammatory bacteria. As a result, all of the disruption in the microbiome could stem from the underlying viral infection.

In conclusion, we appear to be entering the type of shake-up in the field that Thomas Kuhn referred to as a “paradigm shift.”7 All of the elements are there. A well-established concept about a phenomenon fails to account for a growing number of non-conforming bits of evidence. The examination of the bits of evidence reveals a new theoretical model that better explains the phenomenon.

Lastly, the resistance by the established community (in this case the medical community) to give up the old paradigm generates attacks on those who promulgate the new theoretical model, dismissal of the evidence that does not fit the old paradigm, and dogmatic rigidity. Only with great effort is the new paradigm recognized and accepted as correct. We shall see…

References

1. New York Times. http://well.blogs.nytimes.com/2016/07/07/gut-bacteria-are-different-in-people-with-chronic-fatigue-syndrome/?_r=0. Accessed July 8, 2016.

2. Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016 Jun 23;4(1):30.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918027/.

3. Institute of Medicine – Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.http://www.ncbi.nlm.nih.gov/books/NBK274235/. Accessed July 8, 2016.

4. CFS Publications by A. Martin Lerner.http://www.treatmentcenterforcfs.com/cfs_publications/index.html  Accessed July 8, 2016.

5. Henderson, TA. The role of antiviral therapy in chronic fatigue syndrome.http://www.psychiatryadvisor.com/opinion/the-role-of-antiviral-therapy-in-chronic-fatigue-treatment/article/405424/. Accessed July 8, 2016.

6. Henderson TA. Valacyclovir treatment of chronic fatigue in adolescents. Adv Mind Body Med. 2014 Winter;28(1):4-14.

7. Kuhn, T. The Structure of Scientific Revolutions. University of Chicago Press, Chicago IL, Second Edition, 1970.

Posted in News | Tagged , , | Comments Off on CFS is not merely dysbiosis

Dysregulation of protein kinase gene expression in NK Cells in CFS

Research abstract:

BACKGROUND: The etiology and pathomechanism of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) are unknown. However, natural killer (NK) cell dysfunction, in particular reduced NK cytotoxic activity, is a consistent finding in CFS/ME patients.

Previous research has reported significant changes in intracellular mitogen-activated protein kinase pathways from isolated NK cells. The purpose of this present investigation was to examine whether protein kinase genes have a role in abnormal NK cell intracellular signaling in CFS/ME.

METHOD: Messenger RNA (mRNA) expression of 528 protein kinase genes in isolated NK cells was analyzed (nCounter GX Human Kinase Kit v2 (XT); NanoString Technologies) from moderate (n = 11; age, 54.9 ± 10.3 years) and severe (n = 12; age, 47.5 ± 8.0 years) CFS/ME patients (classified by the 2011 International Consensus Criteria) and nonfatigued controls (n = 11; age, 50.0 ± 12.3 years).

RESULTS: The expression of 92 protein kinase genes was significantly different in the severe CFS/ME group compared with nonfatigued controls. Among these, 37 genes were significantly upregulated and 55 genes were significantly downregulated in severe CFS/ME patients compared with nonfatigued controls.

CONCLUSIONS: In severe CFS/ME patients, dysfunction in protein kinase genes may contribute to impairments in NK cell intracellular signaling and effector function. Similar changes in protein kinase genes may be present in other cells, potentially contributing to the pathomechanism of this illness.

Dysregulation of Protein Kinase Gene Expression in NK Cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients, by A Chacko, DR Staines, SC Johnston, SM Marshall-Gradisnik in Gene Regul Syst Bio. 2016 Aug 28;10:85-93

Posted in News | Tagged , , , , , , | Comments Off on Dysregulation of protein kinase gene expression in NK Cells in CFS